<DOC>
	<DOCNO>NCT02261974</DOCNO>
	<brief_summary>Outside United States ( OUS ) Post-Market Parallel Group Exploratory Study Design The objective study determine safety effectiveness Viveve System treat vaginal introitus woman follow vaginal birth ( ) improve vaginal laxity .</brief_summary>
	<brief_title>VIveve Treatment Vaginal Introitus EValuate Effectiveness</brief_title>
	<detailed_description>A prospective , longitudinal , randomize , single-blind , sham control clinical study plan . This study design demonstrate active treatment ( i.e. , Viveve Procedure ) superior sham treatment primary effectiveness safety endpoint . Approximately 145 evaluable subject randomize 2:1 ratio either active treatment group sham group . The active treatment group receive treatment dose 90 J/cm2 sham group receive sub-treatment dose 1 J/cm2 . Subjects follow 72 hr , 10 day , one , two , three , six month post treatment . Final data report 6 month active sham treatment .</detailed_description>
	<criteria>Key 1 . Able understand voluntarily sign informed consent form 2 . Premenopausal â‰¥ 18 year age 3 . At least one full term vaginal delivery ( &gt; 37 complete week gestation ) least 12 month prior enrollment date 4 . Experiences vaginal looseness ( laxity ) vaginal intercourse Key 1 . Pregnant plan become pregnant within next 12 month delivery within last 12 month . 2 . Currently breastfeed discontinue breast feed few 6 month prior enrollment 3 . History genital fistula , thin rectovaginal septum determine investigator history fourth degree laceration screen physical exam ( e.g. , perineal body ) 4 . Clinically significant pelvic organ prolapse 5 . Currently meet criterion female sexual disorder include DSM V , FSAD , FOD , Genitopelvic Pain , Sexual Aversion , Dyspareunia Vaginismus treat condition within past 12 month 6 . Beck Depression Inventory score &gt; 14 7 . DSM5 psychiatric diagnosis exhibit clinically significant symptom 8 . Taking SSNRI SSRI drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Vaginal laxity</keyword>
</DOC>